Matthias Vinther
Principal at Forbion
Matthias Vinther
Principal at Forbion
Amsterdam, North Holland
Overview
Work Experience
Principal
2022 - Current
Forbion is a leading European venture capital firm that helps companies bridge research and development through the team’s expertise in drug development and company building.
Board Observer
2024
Navigator Medicines, Inc. is a biotech company leading the advancement of biologics for targeted immune regulation and restoration.
Board Observer
2024
Capstan Therapeutics, Inc., a biotechnology company dedicated to advancing in vivo reprogramming of cells through targeted lipid nanoparticles
Senior Associate, Novo Ventures
2020 - 2022
Novo Ventures is one of the most active life science venture investors globally. We strive to invest in companies that develop innovative drugs, medical devices and digital health solutions that can potentially improve the health and welfare of people around the world.
Associate, Novo Ventures
2016 - 2019
Board Observer
2018 - 2022
ReViral is a clinical-stage UK-based biotechnology company aiming to help patients affected by life threatening viral infections. Novo Ventures co-led a $55 million Series B investment in ReViral in August 2018. In March 2022, Pfizer acquired ReViral in a deal with a total value of up to $525 million.
Board Observer
2018 - 2022
Stargazer Pharmaceuticals was an ophthalmology focused biotech developing STG001, a novel drug candidate for Stargardt's Disease.
Board Observer
2019 - 2021
VectivBio is a rare disease company with a long-acting GLP-2 agonist, Apraglutide, in short bowel syndrome. Novo Ventures was part of the founding syndicate and participated in the company’s cross-over financing in the fall of 2020. The company successfully listed on NASDAQ Global Select Markets, on 8th of April, 2021 (NASDAQ:VECT).
Board Observer
2016 - 2020
Epsilon-3 Bio was a preclinical stage company focused on the development of first in class drug candidates stimulating safe removal of cellular debris.
Board Observer
2018 - 2019
Therachon was a clinical-stage biotechnology company focused on developing medicines for rare diseases with significant unmet need. Novo Ventures led a $60 million Series B investment in Therachon in August 2018. In July 2019, Pfizer acquired Therachon's TA-46, a phase 1 drug candidate for the rare disease Achondroplasia, for $340 million upfront with a total deal value of $810 million.
Consultative Support Teacher
2010 - 2011
Academic and personal coaching of undergraduate students at Aarhus University